ZA200604545B - Methods for the preparation of stereoisomerically enriched amines - Google Patents
Methods for the preparation of stereoisomerically enriched amines Download PDFInfo
- Publication number
- ZA200604545B ZA200604545B ZA200604545A ZA200604545A ZA200604545B ZA 200604545 B ZA200604545 B ZA 200604545B ZA 200604545 A ZA200604545 A ZA 200604545A ZA 200604545 A ZA200604545 A ZA 200604545A ZA 200604545 B ZA200604545 B ZA 200604545B
- Authority
- ZA
- South Africa
- Prior art keywords
- hydrogen
- alkyl
- aryl
- chosen
- halo
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 57
- 150000001412 amines Chemical class 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 127
- 239000001257 hydrogen Substances 0.000 claims description 127
- 125000000217 alkyl group Chemical group 0.000 claims description 117
- 125000003118 aryl group Chemical group 0.000 claims description 86
- 125000001475 halogen functional group Chemical group 0.000 claims description 76
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 73
- 150000001875 compounds Chemical class 0.000 claims description 58
- 125000000623 heterocyclic group Chemical group 0.000 claims description 54
- 125000001424 substituent group Chemical group 0.000 claims description 48
- 150000002431 hydrogen Chemical class 0.000 claims description 47
- 125000000304 alkynyl group Chemical group 0.000 claims description 30
- 125000003342 alkenyl group Chemical group 0.000 claims description 27
- 239000003960 organic solvent Substances 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 239000003125 aqueous solvent Substances 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 239000011942 biocatalyst Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 108090000371 Esterases Proteins 0.000 claims description 4
- 108091005658 Basic proteases Proteins 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 102000004157 Hydrolases Human genes 0.000 claims description 2
- 108090000604 Hydrolases Proteins 0.000 claims description 2
- 241000588749 Klebsiella oxytoca Species 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 235000019421 lipase Nutrition 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 3
- 241000228212 Aspergillus Species 0.000 claims 1
- 244000063299 Bacillus subtilis Species 0.000 claims 1
- 235000014469 Bacillus subtilis Nutrition 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- 230000001177 retroviral effect Effects 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- 108010010369 HIV Protease Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000004365 Protease Substances 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004030 hiv protease inhibitor Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 101150055869 25 gene Proteins 0.000 description 1
- 241000193422 Bacillus lentus Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/08—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/24—Proline; Hydroxyproline; Histidine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/14—Nitrogen or oxygen as hetero atom and at least one other diverse hetero ring atom in the same ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52714303P | 2003-12-04 | 2003-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200604545B true ZA200604545B (en) | 2007-10-31 |
Family
ID=34652482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200604545A ZA200604545B (en) | 2003-12-04 | 2006-06-02 | Methods for the preparation of stereoisomerically enriched amines |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20050192441A1 (de) |
| EP (1) | EP1737818A2 (de) |
| JP (1) | JP2007521801A (de) |
| KR (1) | KR20060100457A (de) |
| CN (1) | CN101068780A (de) |
| AU (1) | AU2004295187A1 (de) |
| BR (1) | BRPI0417046A (de) |
| CA (1) | CA2549289A1 (de) |
| CO (1) | CO5700727A2 (de) |
| IL (1) | IL175737A0 (de) |
| NO (1) | NO20062944L (de) |
| RU (1) | RU2006119470A (de) |
| WO (1) | WO2005054186A2 (de) |
| ZA (1) | ZA200604545B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007026875A1 (ja) * | 2005-09-02 | 2007-03-08 | Ube Industries, Ltd. | 光学活性（Ｓ又はＲ）－α－ヒドロキシ酸及び光学活性（Ｒ又はＳ）－α－ヒドロキシ酸エステルの製造方法 |
| CN101284797B (zh) * | 2008-06-11 | 2010-08-11 | 常州恩滋生物科技有限公司 | N-保护的烯丙基甘氨酸酯的拆分方法 |
| EP2373977A1 (de) * | 2008-12-17 | 2011-10-12 | The Lubrizol Corporation | Optisch aktive funktionelle flüssigkeitsmarker |
| RU2014106109A (ru) * | 2011-07-20 | 2015-08-27 | Эвоник Дегусса Гмбх | Окисление и аминирование первичных спиртов |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5644028A (en) * | 1992-05-13 | 1997-07-01 | Japan Energy Corporation | Process for producing peptide derivatives and salts therefor |
| US5932550A (en) * | 1995-06-30 | 1999-08-03 | Japan Energy Corporation | Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof |
| US6222043B1 (en) * | 1995-06-30 | 2001-04-24 | Japan Energy Corporation | Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof |
| CA2245543A1 (en) * | 1996-03-13 | 1997-09-18 | Fabienne Henzen | Process for producing n-protected d-proline derivatives 8 |
| AU5757498A (en) * | 1996-12-16 | 1998-07-15 | Lonza A.G. | Method for production of d-proline derivatives |
| HN2002000136A (es) * | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
-
2004
- 2004-11-22 JP JP2006542037A patent/JP2007521801A/ja not_active Withdrawn
- 2004-11-22 WO PCT/IB2004/003812 patent/WO2005054186A2/en not_active Application Discontinuation
- 2004-11-22 BR BRPI0417046-6A patent/BRPI0417046A/pt not_active IP Right Cessation
- 2004-11-22 EP EP04798935A patent/EP1737818A2/de not_active Withdrawn
- 2004-11-22 CN CNA2004800358020A patent/CN101068780A/zh active Pending
- 2004-11-22 AU AU2004295187A patent/AU2004295187A1/en not_active Abandoned
- 2004-11-22 RU RU2006119470/04A patent/RU2006119470A/ru unknown
- 2004-11-22 CA CA002549289A patent/CA2549289A1/en not_active Abandoned
- 2004-11-22 KR KR1020067010848A patent/KR20060100457A/ko not_active Application Discontinuation
- 2004-12-03 US US11/003,830 patent/US20050192441A1/en not_active Abandoned
-
2006
- 2006-05-18 IL IL175737A patent/IL175737A0/en unknown
- 2006-06-01 CO CO06052852A patent/CO5700727A2/es not_active Application Discontinuation
- 2006-06-02 ZA ZA200604545A patent/ZA200604545B/en unknown
- 2006-06-23 NO NO20062944A patent/NO20062944L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007521801A (ja) | 2007-08-09 |
| KR20060100457A (ko) | 2006-09-20 |
| IL175737A0 (en) | 2006-09-05 |
| WO2005054186A2 (en) | 2005-06-16 |
| US20050192441A1 (en) | 2005-09-01 |
| BRPI0417046A (pt) | 2007-02-06 |
| RU2006119470A (ru) | 2007-12-20 |
| CN101068780A (zh) | 2007-11-07 |
| EP1737818A2 (de) | 2007-01-03 |
| NO20062944L (no) | 2006-09-04 |
| CO5700727A2 (es) | 2006-11-30 |
| AU2004295187A1 (en) | 2005-06-16 |
| WO2005054186A3 (en) | 2007-04-19 |
| CA2549289A1 (en) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1066329C (zh) | 药物组合物的制备方法 | |
| AU633017B2 (en) | Therapeutics for aids based on inhibitors of hiv protease | |
| Mimoto et al. | Structure− activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine | |
| WO2002026697A2 (en) | Aromatic derivatives with hiv integrase inhibitory properties | |
| CN110526930B (zh) | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 | |
| DE602007008616D1 (de) | Verfahren zur herstellung von 4'-azidocytidinderivaten | |
| JP2000226329A (ja) | Ｍｍｐ阻害剤 | |
| ZA200604545B (en) | Methods for the preparation of stereoisomerically enriched amines | |
| CA2260128A1 (en) | Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof | |
| JP2007511607A (ja) | セリアック病の薬物療法 | |
| WO2000059867A1 (en) | Hydroxyphenyl derivatives with hiv integrase inhibitory properties | |
| KR20030048424A (ko) | 5-아미디노-2-히드록시벤젠술폰아미드 유도체, 그것을함유하는 의약조성물 및 그 제조중간체 | |
| US6153589A (en) | 2,3-epoxy alcohols, acids and derivatives as anti retroviral chemotherapeutic agents | |
| RU2440351C2 (ru) | Новые ингибиторы цистеиновых протеаз, их фармацевтические композиции и их терапевтическое применение | |
| WO2012088153A1 (en) | Inhibitors of cytochrome p450 | |
| JPH02218654A (ja) | 安息香酸誘導体、それらの製造方法およびそれらを含有する薬剤 | |
| ZA200205854B (en) | Protease inhibitors and their pharmaceutical uses. | |
| KR19980703485A (ko) | 에폭시숙신산 유도체 | |
| AU2020103878A4 (en) | Compounds and methods for treating influenza | |
| CN1104209A (zh) | 2，4-二氨基-3-羟基羧酸衍生物 | |
| CN112724156B (zh) | 一种多环吡啶酮衍生物和药物组合物及其应用 | |
| EP0628035A1 (de) | Retrovirale protease inhibitoren | |
| WO2012088156A1 (en) | Inhibitors of cytochrome p450 | |
| EP4248960A3 (de) | Neuartige triterpenderivate als hiv-hemmer | |
| US6458962B1 (en) | Sultams: catalyst systems for asymmetric reduction of a C=N intermediate biological compositions and methods for making the sultams |